| US 7,598,028 B2 | ||
| Compositions and methods for detecting and treating prostate disorders | ||
| Jill A. Macoska, Ann Arbor, Mich. (US) | ||
| Assigned to The Regents of the University of Michigan, Ann Arbor, Mich. (US) | ||
| Filed on Nov. 28, 2007, as Appl. No. 11/946,676. | ||
| Claims priority of provisional application 60/861346, filed on Nov. 28, 2006. | ||
| Claims priority of provisional application 60/949452, filed on Jul. 12, 2007. | ||
| Prior Publication US 2008/0206766 A1, Aug. 28, 2008 | ||
| Int. Cl. C12Q 1/00 (2006.01); C12Q 33/567 (2006.01); G01N 33/563 (2006.01) | ||
| U.S. Cl. 435—4 [435/7.1; 435/7.23; 436/513; 436/64] | 6 Claims |
| 1. A method for characterizing prostate tissue in a subject, comprising:
a) providing a sample from a subject suspected of having a prostatic disease, wherein said subject has a PSA level at or less
than 10 ng/ml, wherein said sample is selected from the group consisting of prostate tissue, serum, plasma, mucus, blood,
and urine;
b) detecting and comparing the amount of expression of CXCL5 and CXCL12 in said prostate tissue sample; and
c) characterizing said prostate tissue sample as indicative of prostate cancer or benign prostatic hyperplasia based upon
said comparing, wherein a higher amount of detected CXCL12 expression than CXCL5 expression is indicative of prostate cancer,
wherein a higher amount of detected CXCL12 expression than CXCL5 expression is indicative of prostate cancer.
|